This author identifies HuR as a viable therapeutic target for colon cancer, given its role in tumoral growth and survival.491 ERO1α, a protein implicated in poor prognosis in colorectal cancer, was the focus of a study by Takei et al. Knocking out ERO1α via CRISPR/Cas9 revealed its role in promoting cell proliferation and mobility through interactions with cell surface integrin-β1, pointing to new therapeutic targets.492 Ngamkham et al. explored the overexpression of pyruvate carboxylase (PC) in colon cancer and its association with aggressive disease progression and poor survival. Here, ERO1A is linked to malignant colon neoplasm.